Eligibility Colorectal Cancer NCT01326000

Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
adult patients, >/= 18 years of age
Descrizione

ID.1

Tipo di dati

boolean

carcinoma of the colon and/or rectum
Descrizione

ID.2

Tipo di dati

boolean

disease progression during or within 6 months of last dose of oxaliplatin containing first-line combination therapy for metastatic disease
Descrizione

ID.3

Tipo di dati

boolean

ecog performance status 0-1
Descrizione

ID.4

Tipo di dati

boolean

adequate hematological, renal and liver function
Descrizione

ID.5

Tipo di dati

boolean

Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior treatment with monoclonal antibody/small molecule against epidermal growth factor receptor (egfr)
Descrizione

ID.6

Tipo di dati

boolean

prior treatment with irinotecan
Descrizione

ID.7

Tipo di dati

boolean

radiotherapy within the last 4 weeks before first dose of study drug (except for limited field palliative radiotherapy for bone pain relief)
Descrizione

ID.8

Tipo di dati

boolean

cns metastasis
Descrizione

ID.9

Tipo di dati

boolean

history of or active autoimmune disorders/conditions
Descrizione

ID.10

Tipo di dati

boolean

Similar models

Eligibility Colorectal Cancer NCT01326000

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
adult patients, >/= 18 years of age
boolean
ID.2
Item
carcinoma of the colon and/or rectum
boolean
ID.3
Item
disease progression during or within 6 months of last dose of oxaliplatin containing first-line combination therapy for metastatic disease
boolean
ID.4
Item
ecog performance status 0-1
boolean
ID.5
Item
adequate hematological, renal and liver function
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
prior treatment with monoclonal antibody/small molecule against epidermal growth factor receptor (egfr)
boolean
ID.7
Item
prior treatment with irinotecan
boolean
ID.8
Item
radiotherapy within the last 4 weeks before first dose of study drug (except for limited field palliative radiotherapy for bone pain relief)
boolean
ID.9
Item
cns metastasis
boolean
ID.10
Item
history of or active autoimmune disorders/conditions
boolean